Get startedLog in
    Picture of ADC Therapeutics SA logo

    ADCT — ADC Therapeutics SA News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Overland ADCT Biopharma Announces NMPA Accepts Biologics License Application And Grants Priority Review For Zynlonta® For Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

    Picture of ADC Therapeutics SA logoADC Therapeutics SA
    24/07/2023 12:42
    July 24 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * OVERLAND ADCT BIOPHARMA ANNOUNCES NMPA ACCEPTS BIOLOGICS
LICENSE
APPLICATION AND GRANTS PRIORITY REVIEW FOR ZYNLONTA® FOR
TREATMENT OF RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL
LYMPHOMA

Source text for Eikon:  ID:nGNXb4nNT5 
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ADC Therapeutics SA

    See all news